tapebrief

NOC · Q1 2026 Earnings

Bullish

Northrop Grumman

Reported April 21, 2026

30-second summary

Q1 revenue of $9.88B (+4% YoY) beat the "low single digits" framing from January, FY26 guidance was reaffirmed across all four metrics, and management closed the B-21 production-rate acceleration agreement that had been deferred for three consecutive quarters — converting the largest open watch-list item into a positive resolution. The cautious counterweights: Q1 segment OM rate of 10.8% printed below the FY26 "low to mid 11%" framing and the 11.2% Q4 exit, Space Systems contracted 3% after Q4's +5% inflection print, and B-21 acceleration is still explicitly excluded from the reaffirmed FY26 guide — meaning the upside catalyst remains a 2027 event.

Headline numbers

EPS

Q1 FY2026

$6.14

Revenue

Q1 FY2026

$9.88B

+4.0% YoY

Free cash flow

Q1 FY2026

$-1.82B

Operating margin

Q1 FY2026

10.0%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$9.88B+4.0%$11.71B-15.6%
EPS$6.14$7.23-15.1%
Operating margin10.0%10.9%-90bps
Free cash flow$-1.82B$3.23B-156.4%

Guidance

Company reaffirmed full-year FY2026 guidance across all major metrics (revenue, EPS, segment operating income, FCF, margin rate) while Q1 FY2026 beat low single-digit revenue guidance with 4% YoY growth.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ1 FY2026Low single digits YoY growth9.881 billion+4% actual YoY vs low single-digit guide; beat implied ceiling of ~2-3%Beat

New guidance

MetricPeriodGuideYoY
Segment Operating Margin RateQ1 FY202610.8%
Capital ExpendituresFY 2026$1.85 billion
Sequential Sales GrowthQ2 FY2026High single-digit+5-13% YoY

Reaffirmed unchanged this quarter: Revenue ($43.5 billion - $44.0 billion), EPS (non-GAAP / MTM-adjusted) ($27.40 - $27.90), Segment Operating Income ($4,850 million - $5,000 million), Free Cash Flow ($3,100 million - $3,500 million), Segment Operating Margin Rate (Low to mid 11%)

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
Aeronautics Systems$3.283B+17.0%
Defense Systems$1.899B+5.0%
Mission Systems$2.861B+2.0%
Space Systems$2.48B-3.0%

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Net Awards$9.8 billion
Total Backlog$95.6 billion
Segment Operating Margin Rate10.8%
Aeronautics Systems Operating Margin9.3%
Defense Systems Operating Margin9.7%
Mission Systems Operating Margin15.1%
Space Systems Operating Margin9.5%
Organic Sales Growth5%

Management tone

Narrative arc: Sentinel back on track → Generational tailwinds, broad raise → Margin discipline despite revenue retreat → Urgent capacity, but guide still excludes the upside → Capacity now enabling acceleration; weapons elevated to core pillar.

Capacity language completed its arc from "expanding" (Q2) to "tripling" (Q4) to "now enabling acceleration" (Q1). Three quarters ago management was telegraphing doubled SRM capacity. Two quarters ago that escalated to tripling. This quarter the framing flipped from build to harvest: "In the last two years, we've opened over 20 new facilities and added more than 2 million square feet of manufacturing space... we have agreed with our customers on plans to accelerate the Sentinel program, increase the rate at which we build the B-21, become a second source supplier of solid rocket motors on several programs, and ramp our rate of production on another handful of programs." The shift signals that the capacity CapEx of 2024–2025 is now translating to contracted rate increases — a meaningful de-risking of the speculative-CapEx critique that built through 2025.

Weapons reframed from supporting line to core growth pillar. Through 2025 munitions were discussed as a beneficiary of demand and capacity build, but were never quantified as a percentage of company sales. This quarter management put a number on it: "Our weapons business is nearing 10% of total company sales and is positioned to grow at a pace well above the company average." The shift signals that weapons is no longer a feeder to Defense Systems' narrative but a standalone growth thesis approaching the scale of B-21 (also nearing 10%) and matching missile defense (10%). For investors modeling the FY27 step-up, weapons just became a separately trackable line.

B-21 finally moved from "coming months" to deal-in-hand. Q2-25, Q3-25, and Q4-25 all said the deal was imminent and pushed the timeline. This quarter the language is past-tense: "This agreement demonstrates the strong operational requirements for the platform and confidence in our team to accelerate the delivery of this next-generation capability... Importantly, this agreement accelerates production for our customer, enhances the program's long-term economics, and creates the potential for a larger program of record." The Q&A confirmed no meaningful EAC change — offsetting increased production costs with later-phase profitability gains. The credibility hit from three consecutive "coming months" prints is repaired, but the upside is still excluded from the FY26 guide.

Sentinel went from long-cycle to near-term accelerant. A year ago Sentinel was a multi-decade modernization program with IFC pushed to 2033. This quarter management positioned it as a 2026 growth contributor: "We expect strong growth from Sentinel throughout the year as we ramp up on the new baseline, with the program already delivering double digit growth in the first quarter." The Q&A added Sentinel is 6–7% of revenue today with low double-digit growth and milestone B decision later this year. The shift signals milestone density in 2026–2027 that the FY26 guide does not fully capture.

Macro framing escalated from "generational" to "structured demand signals." Q2 framed European NATO commitments as a generational shift; Q3 maintained "unprecedented demand"; Q4 added "transforming Northrop Grumman." This quarter management introduced a new framing: "the administration is working closely with industry to provide clear, long-term demand signals through structured production frameworks." Combined with the $1.5T FY27 budget request (vs. $1.0T FY26 appropriated), management is signaling that the government-contractor relationship itself has shifted toward something more durable than annual appropriations — an unusually forward statement for a defense prime.

Recurring themes management leaned on this quarter:

Government-mandated speed and scale driving production agreementsMulti-billion dollar capacity investments now yielding acceleration across programsMunitions and solid rocket motors emerging as major growth vectorsMissile defense as critical capability area with exceptional demandGeopolitical urgency translating to record defense spending ($1.5T FY27 request)Unprecedented partnership model with DoD enabling aligned execution

Risks management surfaced:

Forward-looking statements subject to risks and uncertainties noted in SEC filingsGEN63 XL program unfavorable earnings adjustment of $71 million recognized in Q1FA-18 volume declines offsetting growth in other segmentsHypersonic missile proliferation requiring accelerated GPI developmentProduction ramp execution risk on B-21 and Sentinel requiring $2.5B+ company-funded investment

Q&A highlights

Christine Levi · Morgan Stanley

How can Northrop Grumman achieve double-digit growth given mid-single-digit guidance, and what are the key bottlenecks? Additionally, how should investors think about Northrop's positioning on the FAXX contract with potential award in Q3 and upside to 2026 outlook?

Management outlined multiple levers for higher growth: bidding on new opportunities, winning at high competitive rates, accelerating missile component demand (especially solid rocket motors), converting international pipeline to sales, and removing supply chain bottlenecks. On FAXX, Northrop is confident in its ability to deliver, has suppliers prepared, and expects upside to sales and earnings if selected in Q3. The company would make it a top priority.

Backlog at $96 billion, providing 2+ years sales coverageMid-single-digit growth expected in 2026FAXX award expected Q3 2026B-21 track record demonstrates ability to execute complex aircraft on schedule

Sheila Kayalu · Jefferies

What are the revenue and earnings profiles for the four key growth drivers: B-21, Sentinel, missiles, and missile defense? When will these programs inflect?

Sentinel is 6-7% of revenue, growing low double-digits with production long-lead inflection later this decade. B-21 nearing 10% of revenue and expected to exceed 10% over next several years. Weapons (munitions and prime integrator position) at ~10% expected to be one of fastest growers. Missile defense at 10% of revenue. All four programs have margin upside as they move from development into production phases.

Sentinel: 6-7% of company revenue today, low double-digit growth expectedB-21: nearing 10% of revenue, expected to exceed 10% in coming yearsWeapons portfolio: ~10% of revenue, expected to be one of fastest-growing segmentsMissile defense: 10% of company sales

Robert Stallard · Vertical Research

What is the timeline for B-21 capex spending and production flow, and what protections exist against B-2 style curtailment?

Management expects $200 million capex this year with majority of capital expenditure in 2027-2029 timeframe, largely completed this decade. Additional capacity will generate meaningful revenue increase over program life, with revenue profile following production facility completion. B-21 is protected by committed quantity on contract, and Air Force is considering increasing program of record. Strong administration support for capability driven by triad modernization and national defense strategy.

$200 million capex expected in 2026Majority of capex in 2027-2029 timeframeCommitted quantity on B-21 contract provides protectionAir Force considering increasing program of record

Scott Mikus · Milius Research

Are European customers becoming wary of ordering from U.S. companies due to uncertainty about delivery timelines given competing U.S. demand priorities?

European demand remains robust despite sensitivities around delivery timelines and preference for local suppliers. Northrop is investing in capacity (20 facilities opened in last 24 months, 2+ million sq ft manufacturing space) and can meet both U.S. and European commitments without trading off one for the other. Space business has least international pipeline but expected to grow significantly.

20 facilities opened in last 24 months2+ million square feet of manufacturing space addedEuropean customers remain sensitive to U.S. delivery timelinesSpace segment has least international pipeline but growing

Seth Seifman · JP Morgan

On the B-21 production agreement, what portion of profitability improvements will come from LRIP unit reversals versus NTE units? Also, how should investors think about offsetting $2.5 billion capex investment over 2027-2028 against the 2028 cash flow target?

The production agreement improved overall program economics with no meaningful EAC change—offsetting increased production costs with later-phase profitability gains. No specific guidance on LRIP reversal timing; profitability improvements expected from manufacturing capability and production rate improvements. Company did not provide 2027-2028 cash flow guidance due to large awards outstanding and capex timing, but emphasized strong cash generation power of the business will continue.

B-21 agreement resulted in no meaningful EAC change overallIncreased production costs offset by later-phase profitability gainsROAC expected to be meaningfully above cost of capital$2.5 billion capex primarily in 2027-2028

Answers to last quarter's watch list

B-21 acceleration deal close by Q1 print. Resolved positively. Management closed the deal this quarter — the production-rate acceleration agreement is signed, with the Q&A confirming no meaningful EAC change, later-phase profitability gains offsetting near-term cost increases, and the potential for an expanded program of record. The three-quarter credibility overhang is closed. The qualifier is that the acceleration is still NOT in the FY26 guide, deferring P&L impact to 2027+.
Resolved positively
FY26 revenue guide trajectory. Q1 revenue of $9.88B grew 4% YoY, beating the "low single digits" framing (typically 1–3%). Organic growth ran 5%. Q2 is guided high single-digit sequentially, implying ~$10.6–10.8B against the $10.35B Q2-25 base — roughly +2–4% YoY, consistent with the back-half-weighted FY guide. The setup is cleanly above the low-end trajectory.
Resolved positively
Segment OM rate vs. FY26 implied ~11.2%. Q1 segment OM rate of 10.8% printed below the 11% concern threshold and 40bps below the Q4-25 exit of 11.2%. Management framed this as 1H timing and reaffirmed the "low to mid 11%" FY range, citing production mix and timing as the recovery levers. The Q1 print is unfavorable relative to the bull case that FY26 guidance was conservative.
Resolved negatively
IDCS award conversion. The press release and call materials available do not surface specific IDCS country-award announcements this quarter. International commentary was framed via overall European demand and 18% growth carryforward, not via new country signatures. The company didn't disclose discrete IDCS wins on the print.
Continue monitoring
Capital return decisions at Q2 print. No capital return update was disclosed in the available Q1 materials; the May board dividend decision was not pulled forward to the Q1 print. The CapEx framing tightened ($200M near-term, majority in 2027–2029, $1.85B total 2026) and 2027–2028 cash flow guidance was explicitly deferred — both consistent with a "fund the capacity build first" posture.
Continue monitoring
GEM 63 inflection in 2027. The Q1 print disclosed a $71M unfavorable EAC adjustment on GEN63 XL — the first discrete charge management has surfaced on the speculative-capacity build. No new 2027 volume commentary was supplied. The charge is contained but it's the wrong direction for the "speculative CapEx converting cleanly to backlog" thesis.
Resolved negatively

What to watch into next quarter

FAXX award decision in Q3. Management characterized FAXX as a top priority with suppliers prepared and explicit upside to 2026 sales and earnings. A win is a discrete catalyst that would force a mid-year guide raise; a loss removes the cleanest 2026 upside lever and leaves NOC's near-term growth dependent entirely on backlog conversion. Watch for any guide commentary at Q2 print that pre-positions for either outcome.

Q2 segment OM rate recovery toward 11%+. Q1 at 10.8% needs to trend up to validate the "low to mid 11%" FY guide. If Q2 prints flat or down — call it sub-11% again — the FY segment income guide of $4,850–5,000M comes under pressure and the "margins improve over the course of the year" framing loses credibility.

Mission Systems growth re-acceleration. Q1 +2% was a sharp deceleration from Q3-25 +10% and Q4-25 +10%. Without transcript-level explanation, this is the cleanest negative data point in the print. Watch whether Q2 recovers to mid-to-high-single-digits — if it stays at low-single-digits, the FY broad-based growth thesis carries less weight.

Space Systems back to positive growth. Q4-25 inflected to +5%; Q1-26 fell back to -3%. The "all four segments growing" line from January did not hold. A Q2 return to flat or positive validates the program wind-down lap as complete; a third negative print forces a rethink on Golden Dome contribution timing.

GEN63 XL EAC stability. The $71M Q1 charge is the first crack in the speculative-SRM-CapEx thesis. Watch whether Q2 carries any additional unfavorable EAC adjustments, or whether management quantifies a 2026 volume floor that protects the program economics.

Book-to-bill recovery above 1.0x. Q1's 0.99x is the first sub-1x quarter since Q2-25 and the headline backlog ticked down $0.1B QoQ. A second sub-1x quarter while management is signaling "structured production frameworks" from DoD would be a meaningful inconsistency. Watch for a 1.1x+ Q2 print to restore the backlog growth trajectory.

Capital return posture at Q2 print. Buybacks were suspended beyond January 2026 and the May dividend decision was deferred. Whether NOC reinstates buybacks, raises the dividend, or holds both back will signal management's read on whether the 2027–2028 CapEx and B-21 investment cycle is fully self-funded.

Sources

  1. NOC Q1 2026 earnings release (SEC filing): https://www.sec.gov/Archives/edgar/data/1133421/000113342126000015/noc-03312026xearningsrelea.htm
  2. NOC Q1 2026 earnings call commentary (as captured in tone and Q&A extraction)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.